Home – Page 38 – The Cancer Letter

Issue 35 - Sep 21, 2018

TCL44-35 (310 downloads)

As José Baselga clears his desk, MSK forms task force on conflicts; meanwhile, new allegations emerge over center’s role in AI start-up
José Baselga, who has resigned from his positions as physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center, is winding down his research and clinical activities at that institution, officials said.
Senate passes conference bill, giving NIH $2 billion raise
The U.S. Senate Sept. 18 passed a conference “minibus” appropriations package that will increase the NIH budget by $2 billion to $39.1 billion—a 5.4 percent boost over the current level.
In Brief
- Soria, Mok, Jänne, and Foti win ESMO 2018 awards
- Blackwood named chief of breast surgery at Rutgers Cancer Institute
- Madhavan named chief data scientist at Georgetown
- AbbVie donates $5 million to Family Reach
- Six health systems join the Syapse Learning Health Network
- CancerCare to provide support for cancer patients affected by Hurricane Florence
Trials and Tribulations
Shrinking oncology phase I clinical trials: If the drug is a breakthrough, why would you ever want to utilize the maximally tolerated dose?
Historically, oncology drug development has evolved on what may seem to be a different planet, at least relative to mainstream clinical pharmacology.
Whereas traditional drug development utilizes standard tools of randomization, pharmacokinetic data, and blood-based biomarkers to optimize dosing, oncology has primarily utilized safety data (i.e., maximally tolerated dose) to guide dose selection.
Clinical Roundup
- Early positive results from phase II DPX-Survivac + Keytruda in DLBCL
Drugs & Targets
- European Commission approves Braftovi + Mektovi for advanced BRAF-mutant melanoma
- OBI Pharma granted Orphan Drug Designation for treatment of ALL

Issue 34 - Sep 14, 2018

TCL44-34 (895 downloads)

José Baselga resigns as physician-in-chief at Memorial Sloan Kettering
José Baselga has resigned from his position as physician-in-chief and chief medical officer of Memorial Sloan Kettering Cancer Center less than a week after The New York Times and ProPublica reported that he had failed to disclose his conflicts of interest in scientific and medical journals and at professional meetings.
A color-coded document Baselga created to explain himself instead illustrated the extent of his confusion and exposure
The discussions that took place in the executive offices of Memorial Sloan Kettering Cancer Center over the past week aren’t publicly known. Ditto conversations at top-tier medical journals and professional societies, which are assessing the aftermath of José Baselga’s systematic failure to disclose his conflicts of interest.
ASCO urges CMS to drop proposal that threatens to reduce access for Medicare cancer patients
Through a combination of payment reductions, some provisions of the 2019 Medicare Physician Fee Schedule proposed rule will undermine access to cancer care for Medicare beneficiaries, the American Society of Clinical Oncology wrote in a comment letter to the Centers for Medicare & Medicaid Services.
In Brief
- Nearly 350 groups join AACR in Rally for Medical Research
- Stand Up To Cancer 2018 telecast raises $123.6 million
- Allis, Grunstein, Glen, Steitz win 2018 Lasker Awards
- $3.2 million NIH grant aims to correct diagnostic errors for breast cancer
- CPRIT surpasses $2 billion milestone with 64 new grants
- Sidney Kimmel – Jefferson joins Driver network
- Three community health care systems to use Flatiron’s OncoCloud Suite
Funding Opportunities
NCCN-Lilly RFP on quality of care in gastric cancer
The National Comprehensive Cancer Network announced a collaboration with Eli Lilly and Co. to offer a new opportunity seeking proposals to bridge gaps in care for gastric and gastroesophageal junction cancer patients in the U.S. The Request for Proposals outlines the scope and process that will be followed for the submission of Letters of Intent.
Clinical Roundup
- Study details incidence and timing of immunotherapy-related fatalities
- CARsgen Therapeutics and CrownBio complete CAR-T study for gastric cancer
- Bavencio + Inlyta improved PFS in advanced RCC
- IMV Inc. and Merck to evaluate DPX-Survivac + Keytruda
- Clinical trial shows best outcomes to date for older Hodgkin lymphoma patients
- Children who develop ALL may have dysregulated immune function at birth
- Drug for pancreatic cancer targets two genes at a time
Drugs & Targets
- FDA approves moxetumomab pasudotox-tdfk for hairy cell leukemia
- Boehringer Ingelheim acquires all ViraTherapeutics shares to develop next-gen viral-based therapies

Issue 33 - Sep 7, 2018

TCL44-33 (282 downloads)

To “free the data,” expert group urges NCI to spend money to speed up data sharing
A working group formed by NCI Director Ned Sharpless has recommended that the institute devote additional funds informatics researchers could use to harmonize existing cancer datasets.
Twitter star Vinay Prasad retires @VinayPrasadMD
Vinay Prasad, a cyber-iconoclast for all things cancer, appears to have closed the Twitter account that made him a brand in oncology.
Mendelsohn retires from MD Anderson
John Mendelsohn has retired from MD Anderson Cancer Center, which he served as president for 15 years, from 1996 to 2011.
Obituary
Radiation oncology pioneer Moody Wharam, dies at 77
Moody Wharam Jr., professor emeritus of radiation oncology and molecular radiation sciences, and former Willard and Lillian Hackerman Professor of Radiation Oncology at the Johns Hopkins Kimmel Cancer Center, died Aug. 10 at age 77.
In Brief
- Northwestern Lurie Cancer Center earns “exceptional” rating from NCI
- Northwestern awarded brain cancer SPORE grant
- Rogel Cancer Center awarded CCC designation and $33.4M from NCI
- Rutgers Cancer Institute redesignated as comprehensive cancer center
- Bernard Fisher turns 100
- Agios announces CEO succession plan
- Ruth McCorkle named AAN Living Legend
- Vamsidhar Velcheti named director of thoracic medical oncology at NYU
- NYU Langone’s Perlmutter Cancer Center expands blood, marrow transplant program
- Siteman Cancer Center expands to Illinois
- ACS selects first project in “accelerator pipeline”
- Smith, Thompson, Yau receive LUNGevity Career Development Awards
- bluebird bio, Gritstone Oncology form collaboration to develop cancer cell therapies
- JNCCN strengthens focus on original, impactful research into care delivery
Clinical Roundup
- SOLAR-1 trial of Novartis meets primary endpoint in HR+/HER2- advanced breast cancer
- PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations
- NCI-led research team develops predictor for immunotherapy response in melanoma
- Cetuximab + radiation found inferior to standard treatment in HPV-positive oropharyngeal cancer
- Secondhand smoke exposure in childhood may raise risk of adult lung disease
- Mount Sinai researchers create RNA and DNA-sequencing platform to match broader swath of cancer drugs
- Duke researchers find missing immune cells that could fight lethal brain tumors
- Hopkins researchers seeking ways to monitor effectiveness of immunotherapy
Drugs & Targets
- Kymriah gets European approval for B-cell ALL and diffuse large B-cell lymphoma indications
- FDA gives priority review to BMS Empliciti + pomalidomide, dexamethasone in multiple myeloma
- Rafael Pharmaceuticals receives FDA Orphan Drug Designation of CPI-613 for peripheral T-cell lymphoma
- ASLAN003 gets Orphan Drug Designation for AML

Page 38 of 117« First «...10 20...34 35 36 373839 40 41 42 43...50 60 70 80 90 100 110...»Last »